Loading…
Diagnostic and management strategies in cardiac sarcoidosis
Cardiac sarcoidosis (CS) is increasingly recognized in the context of with otherwise unexplained electrical or structural heart disease due to improved diagnostic tools and awareness. Therefore, clinicians require improved understanding of this rare but fatal disease to care for these patients. The...
Saved in:
Published in: | International journal of cardiology 2024-05, Vol.403, p.131853-131853, Article 131853 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Cardiac sarcoidosis (CS) is increasingly recognized in the context of with otherwise unexplained electrical or structural heart disease due to improved diagnostic tools and awareness. Therefore, clinicians require improved understanding of this rare but fatal disease to care for these patients. The cardinal features of CS, include arrhythmias, atrio-ventricular conduction delay and cardiomyopathy. In addition to treatments tailored to these cardiac manifestations, immunosuppression plays a key role in active CS management. However, clinical trial and consensus guidelines are limited to guide the use of immunosuppression in these patients. This review aims to provide a practical overview to the current diagnostic challenges, treatment approach, and future opportunities in the field of CS.
•Cardiac sarcoidosis (CS) should be considered in the right clinical context.•The cardinal manifestations of CS include conduction disease, arrhythmia or heart failure.•Immunosuppression is the cornerstone of treatment though with limited consensus data.•Heart failure and arrhythmia management are key components of multidisciplinary CS patient care. |
---|---|
ISSN: | 0167-5273 1874-1754 |
DOI: | 10.1016/j.ijcard.2024.131853 |